 REINDUCTION BLOCK 1: Patients receive cytarabine intrathecally IT on day 1; vincristine sulfate IV over 1 minute on days 1, 8, 15, and 22; doxorubicin hydrochloride IV over 15 minutes on day 1; prednisone orally PO twice daily BID on days 1-28; bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11; and pegaspargase intramuscularly IM or IV over 1-2 hours on days 2, 8, 15, and 22. Patients with central nervous system CNS-negative disease CNS1 or CNS2 also receive methotrexate IT on days 15 and 29; patients with CNS-positive disease CNS3 receive triple intrathecal therapy TIT comprising methotrexate, hydrocortisone, and cytarabine IT on days 8, 15, 22, and 29. After completion of reinduction block 1, patients with ALL and M2 or M3 bone marrow proceed directly to reinduction block 2. Patients with ALL and M1 bone marrow or lymphoblastic lymphoma proceed to reinduction block 2 after blood counts recover. Patients with persistent cerebral spinal fluid CSF blasts after 6 doses of TIT or patients with progressive lymphoblastic lymphoma are removed from the study. 